Title Category Credit Event date Cost
ACC 2019: Duration Of Diabetes And Cardiorenal Efficacy Of Liraglutide And Semaglutide - Prof Subodh Verma
£0.00 Prof Subodh Verma (University of Toronto, Toronto, CA) discusses his poster presented at the ACC 2019 entitled duration of diabetes and cardiorenal efficacy of liraglutide and semaglutide - a post hoc analysis of the LEADER and SUSTAIN-6 Clinical Trials.Filmed on site at ACC 2019 by Radcliffe Cardiology Videography: Josh BirchInterviewer: Liam O'Neill
Convergent procedure: A new approach to atrial fibrillation ablation
  • European Board for Accreditation in Cardiology (EBAC)
£0.00 OverviewThe cornerstone of atrial fibrillation (Afib) is electrical isolation of the pulmonary veins (PV).
Utilizing NOAC's in non-valvular atrial fibrillation patients undergoing PCI
  • Attendance
£0.00 OverviewThis independent medical education (IME) series has been created  for English, German and Spanish speaking cardiologists and is designed to showcase the latest updates emerging from the data in novel oral anticoagulants in non-valvular atrial fibrillation patients undergoing PCI.
Hybrid ablation: a role in AF management?
  • European Board for Accreditation in Cardiology (EBAC)
£0.00 OverviewJoin a panel of International faculty as they discuss the clinical value of hybrid ablation treatment strategies for persistent atrial fibrillation (AF).Can it improve patient outcomes? What evidence base is available to support this? How can it be implemented effectively in clinical practice?Available from 06/07/2018 until 06/07/2023. 
A Review of Emerging ARNI Data in HFrEF
  • European Board for Accreditation in Cardiology (EBAC)
£0.00 OverviewDespite advances in cardiovascular therapy, heart failure (HF) continues to be a leading cause of morbidity and mortality with significant cost to the health care system. Evidence for the angiotensin receptor-neprilysin inhibitor (ARNI) sacubitril/valsartan has demonstrated significant reductions in all-cause mortality, cardiovascular mortality, and HF hospitalization compared with enalapril and international guidelines currently recommend its use.
Current and Emerging Data on SGLT2 Inhibitors in Heart Failure
  • European Board for Accreditation in Cardiology (EBAC)
£0.00 OverviewThe opportunity for cardiovascular disease prevention in patients with type 2 diabetes mellitus (T2DM) has recently expanded with antihyperglycemic agents demonstrating significant reductions in the risk of major adverse cardiovascular events (MACE) including sodium-glucose co-transporter-2 (SGLT2) demonstrating robust reductions in heart failure (HF).